Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNF114 | Q9Y508 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.38 |
| ▸ | USP2 | O75604 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimbolide SCHEMBL26312156 | 1.00 | RNF114 (1.00) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| Nimbolide SCHEMBL23483973 | 1.00 | RNF114 (1.00) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| Nimbolide SCHEMBL2146198 | 1.00 | RNF114 (1.00) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| Nimbolide SCHEMBL21163877 | 1.00 | RNF114 (1.00) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| SCHEMBL26698833 | 0.93 | RNF114 (0.86) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| SCHEMBL24076795 | 0.92 | RNF114 (0.86) | RNF114HSP90AA1BRD4CYP3A4USP2 | |
| SCHEMBL24625130 | 0.90 | RNF114 (0.82) | RNF114HSP90AA1BRD4CYP3A4 | |
| SCHEMBL24076672 | 0.88 | RNF114 (0.78) | RNF114HSP90AA1BRD4 | |
| SCHEMBL24625481 | 0.88 | RNF114 (0.78) | RNF114HSP90AA1BRD4 | |
| SCHEMBL24076520 | 0.86 | RNF114 (0.76) | RNF114HSP90AA1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | RNF114 1559/4885HSP90AA1 1470/4885BRD4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.